戻る Agenda
SESSION 3
Session Chair(s)
Toshiyoshi Tominaga, PhD
Project Professor
Keio University Hospital, Japan
Session 3
Speaker(s)
Panel Discussion
Pär Tellner, MPharm, MSc, RPh
EFPIA - European Federation of Pharmaceutical Industries and Associations, Belgium
Director, Regulatory, Drug development and Manufacturing
E9 Improving Planning, Conduct, Analysis and Interpretation of Clinical Trials
Steven Teerenstra, PhD, MSc
Medicines Evaluation Board, Netherlands
Statistician
E14 Clinical Evaluation of QT/QTc
Corina Dana Dota, MD
AstraZeneca R&D Molndal, Sweden
AZ ECG Centre Director
M4E (CTD) Benefit-Risk Information
Filip Mussen, PhD
Janssen R&D, Pharmaceutical Companies of Johnson & Johnson, Belgium
Vice President, Regional Regulatory Affairs
Panel Discussion
Tomas Salmonson, DrMed, PhD
Critical Path Institute, United States
Partner